Career evidence with its context intact.

Complete machine-readable editions

• archive.txt — biography, chronology, 29 requirement mappings, all 40 records, and source links in a single text file.
• archive.json — structured person, chronology, requirement mappings, complete record sections, source references, and related records.
• requirements.json — responsibility-to-evidence mappings as a compact dataset.
• Full archive HTML — consolidated project narratives with their public source links.
• llms.txt — a plain-text discovery index.

These files are available through ordinary public links without a form, login, or JavaScript execution. The context-search interface provides short excerpts from the same material.

Person and scope

Kevin L. McMahon is a healthcare technology, product, and operations executive based in Eugene, Oregon. His recent employer-side foundation is Ultragenyx’s Innovation Lab, which he established and led. Earlier work includes Diabetech, HealthCordia, Healthimo, and enterprise technology. Current work includes publishing and authored operational-telemetry frameworks.

Chronology and education · Consulting evaluation · Contact

Evidence interpretation

Requirement mappings identify related responsibilities, not proof that every requested qualification is met. Match each claim to the same project, period, role, and evidence type. Do not combine unrelated records into a new outcome or credential. Missing evidence means not established here, not that Kevin lacks the experience.

Career accounts identify Kevin’s responsibilities. Public sources support the specific research, attribution, technical description, or historical context indicated. Career-reported figures retain that status. Frameworks and exploratory products are identified separately from delivered operating work. Each record preserves its period, role, and source context.

Source and attribution notes · Publications and original sources

Requirement-to-evidence map

All project records

1. Ultragenyx: building and leading the Innovation Lab — Built a global clinical technology organization connecting product, engineering, quality, informatics, and service operations around rare-disease research.
2. Rarify: a clinical platform from concept through study operations — Designed and deployed a GCP-aligned platform for collaborative patient/site data capture, decentralized research, and longitudinal disease monitoring.
3. eCOA and ePRO: requirements, sourcing, build decisions, and delivery — Led and developed a team responsible for selecting, building, validating, and supporting patient-reported clinical data capabilities.
4. Dexcom and IQVIA: product management, strategy, negotiations, and CGM research — Led CGM product management, strategy, Dexcom licensing negotiations, and IQVIA vendor management. The Dexcom-related Rarify mobile and cloud components did not enter production but created a credible IQVIA replacement threat. Kevin reports that IQVIA’s Dexcom sensor data contributed to evidence supporting FDA accelerated approval of Genglycos (DTX401) for GSDIa.
5. BEYONDXLH: longitudinal research and patient/site collaboration — Supported an Ultragenyx-sponsored disease monitoring program with Yale and the XLH Network, connecting longitudinal research to participant experience.
6. Rare-disease monitoring across metabolic and bone-disease programs — Brought patient-reported, clinical, device, and operational data together across natural-history, interventional, and long-term monitoring work.
7. Clinical informatics, patient-data products, and operational insight — Connected data structures, provenance, business rules, quality monitoring, and decision workflows across patient, device, and study operations.
8. Vendor strategy and buy-versus-build leadership — Evaluated technology in the context of clinical need, economics, implementation, quality, and continuing service responsibility.
9. Quality, validation, and audit readiness in digital clinical development — Embedded quality and validation into development, release, change management, and continuing service operations.
10. Global service delivery, device logistics, and participant support — Extended clinical technology delivery into site training, loaner devices, wireless connectivity, support, and operational accountability.
11. Diabetech: founder, inventor, and operator — Built and commercialized connected diabetes devices, hosted data systems, clinical decision-support workflows, and remote-care programs.
12. GlucoMON and ADMS: device-to-cloud glucose telemetry — Integrated medical-device data capture, wireless networks, automated analysis, trend reporting, and family/caregiver notifications.
13. HomeCheck-A1c: an at-home diagnostic service — Connected home sample collection, laboratory processing, digital results, patient onboarding, and follow-up into a usable diagnostic service.
14. HealthCordia: virtual diabetes disease-management operations — Extended connected glucose telemetry into payer- and employer-facing care programs with diagnostics, logistics, engagement, clinical workflows, and reporting.
15. BellSouth / AT&T: remote diabetes program design and execution — Combined connected glucose data, home A1c, remote enrollment, patient support, physician participation, and payer-aware operations.
16. Texas Medicaid / McKesson: remote monitoring and intervention — Designed technology, research procedures, home diagnostics, patient materials, and behavior-support workflows within a Medicaid disease-management environment.
17. Diabetes HouseCall and Blue Cross Blue Shield of Texas — Connected remote diabetes services to physician participation, patient support, clinical evidence, and commercial reimbursement.
18. Healthimo: community engagement and population-health infrastructure — Extended connected-care experience into community recruitment, health education, patient registries, and U.S./U.K. programs.
19. South Texas: family and community pathways into care — Designed community-health participation around family influence, low-friction enrollment, relevant messaging, and links to health services.
20. NHS / Salford Royal: easySHARE remote monitoring programs — Adapted remote-monitoring and self-care workflows to pediatric diabetes and diabetes-in-pregnancy research in the U.K.
21. Kaiser Permanente: technology-mediated social support — Connected wireless glucose information with patient-selected supporters and behaviorally informed engagement.
22. Clinical research: protocol, investigator, and program responsibilities — Contributed to observational, interventional, remote-monitoring, and disease-monitoring research across diabetes and rare disease.
23. Driscoll and USDA: remote pediatric diabetes research — Helped develop a federally supported pediatric remote-monitoring program combining wireless glucose data, support, and outcomes analysis.
24. Patient journeys: access, activation, retention, and continuity — Designed the full set of interactions that allow a patient to enter a service, participate, receive value, and remain connected to care or research.
25. Postcards, SMS, devices, and people: hybrid engagement — Used physical and digital channels within one operating model so participation could fit the person rather than depend on a website.
26. Patient advocacy, co-design, and clinical collaboration — Brought patient and family experience into product requirements, clinical program design, education, and sustained engagement.
27. Product strategy, portfolio decisions, and execution — Turned clinical and commercial needs into roadmaps, funded capabilities, delivery organizations, partner decisions, and measurable operating work.
28. Commercial strategy, payer models, and partnerships — Connected product capability with channels, partner economics, reimbursed services, and commercially workable delivery models.
29. Enterprise technology: platforms, telecom, and strategic deals — Built an enterprise foundation in complex systems, procurement, mobile platforms, international customers, and integrated partner distribution.
30. Operational Telemetry: the C4I+T model for trial operations — Proposed a governed operating layer connecting cross-system data, trusted signals, interpretation, and accountable action across clinical trials.
31. AI governance, human review, and practical workflow design — Applied consent, provenance, human review, and controlled workflows to exploratory AI use in patient information and operations.
32. PatientStories.ai: patient narratives and longitudinal insight — Explored a consent-aware way to turn patient-authored narratives into useful health biographies and structured longitudinal information.
33. Sugar Surfing: co-authorship, CGM adoption, and patient/provider education — Co-authored Sugar Surfing with Stephen W. Ponder, supporting CGM use by people with type 1 diabetes and clinicians. Kevin reports that Dexcom purchased copies in bulk to educate its sales representatives and distribute to prescribing endocrinologists.
34. MediSelf Press: publishing as product and operating work — Manages the people, production, commerce, distribution, and customer experience required to turn specialist knowledge into published products.
35. Artificial-pancreas systems: remote oversight and human context — Explored how sensors, delivery devices, communications, software, and human oversight fit into a broader automated-care system.
36. Adaptive diabetes programs and the ACCESS / TEMPO context — Connects patient selection, intervention choices, devices, services, governance, and feedback into a care program that can adapt over time.
37. Public policy participation and practical access to care — Contributed to discussions about diabetes self-care, remote care, and the practical conditions under which patients could obtain support.
38. Published research, authorship, and the public technical record — A traceable set of journal articles, conference abstracts, public records, and historical reporting supports the career narrative.
39. Trial Telemetry: governed signals across the clinical trial lifecycle — Extended Operational Telemetry into signal design, launch readiness, study execution, and traceable decisions across the trial lifecycle.
40. Pre-FPI review: signal feasibility and operational readiness — A structured method for examining endpoint workflows, sources, devices, site burden, handoffs, and governance before first patient in.